Literature DB >> 12360327

Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning.

Dale Schenk1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12360327     DOI： 10.1038/nrn938

Source DB:  PubMed          Journal:  Nat Rev Neurosci        ISSN： 1471-003X            Impact factor:   34.870


× No keyword cloud information.
  120 in total

1.  Linear and conformation specific antibodies in aged beagles after prolonged vaccination with aggregated Abeta.

Authors:  Vitaly Vasilevko; Viorela Pop; Hyun Jin Kim; Tommy Saing; Charles C Glabe; Saskia Milton; Edward G Barrett; Carl W Cotman; David H Cribbs; Elizabeth Head
Journal:  Neurobiol Dis       Date:  2010-05-06       Impact factor: 5.996

Review 2.  Intercellular (mis)communication in neurodegenerative disease.

Authors:  Gwenn A Garden; Albert R La Spada
Journal:  Neuron       Date:  2012-03-08       Impact factor: 17.173

Review 3.  Vaccines for Alzheimer's disease: how close are we?

Authors:  Christopher Janus
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

4.  Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology.

Authors:  Frédérique Bard; Robin Barbour; Catherine Cannon; Robert Carretto; Michael Fox; Dora Games; Teresa Guido; Kathleen Hoenow; Kang Hu; Kelly Johnson-Wood; Karen Khan; Dora Kholodenko; Celeste Lee; Mike Lee; Ruth Motter; Minh Nguyen; Amanda Reed; Dale Schenk; Pearl Tang; Nicki Vasquez; Peter Seubert; Ted Yednock
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-03       Impact factor: 11.205

5.  Attack on amyloid.

Authors:  Philipp J Kahle; Bart De Strooper
Journal:  EMBO Rep       Date:  2003-07-25       Impact factor: 8.807

6.  Lessons learned at the intersection of immunology and neuroscience.

Authors:  Lawrence Steinman
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

7.  Low concentrations of anti-Aβ antibodies generated in Tg2576 mice by DNA epitope vaccine fused with 3C3d molecular adjuvant do not affect AD pathology.

Authors:  Nina Movsesyan; Hayk Davtyan; Mikayel Mkrtichyan; Irina Petrushina; Tigran Tiraturyan; Ted Ross; Michael G Agadjanyan; Anahit Ghochikyan; David H Cribbs
Journal:  Hum Gene Ther       Date:  2010-11       Impact factor: 5.695

8.  Abeta42 gene vaccine prevents Abeta42 deposition in brain of double transgenic mice.

Authors:  Bao-Xi Qu; Qun Xiang; Liping Li; Stephen Albert Johnston; Linda S Hynan; Roger N Rosenberg
Journal:  J Neurol Sci       Date:  2007-06-15       Impact factor: 3.181

9.  Increased T cell recruitment to the CNS after amyloid beta 1-42 immunization in Alzheimer's mice overproducing transforming growth factor-beta 1.

Authors:  Marion S Buckwalter; Bronwen S Coleman; Manuel Buttini; Robin Barbour; Dale Schenk; Dora Games; Peter Seubert; Tony Wyss-Coray
Journal:  J Neurosci       Date:  2006-11-01       Impact factor: 6.167

Review 10.  Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.

Authors:  Einar M Sigurdsson
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.